Objectives: A possible mechanism for HIV therapy failure is the efflux of HIV drugs from viral target cells or certain body compartments by ATP-binding cassette (ABC) transporters, allowing ongoing viral replication. Here, we investigated the interaction between protease inhibitors (PIs) and ABC transporters.
Introduction
Since the introduction of combination antiretroviral therapy (cART) for HIV infection, treatment failure has become increasingly uncommon. Nevertheless, therapy failure remains an important problem.
HIV therapy failure is often the result of viral resistanceassociated mutations. The virus has had the ability to mutate due to insufficient drug concentrations often related to drug non-adherence (not taking medication as prescribed) or caused by (temporary) decreased bioavailability (e.g. in the case of drug interactions or diarrhoea). However, sometimes therapy failure occurs while the patient is adherent and has adequate plasma drug concentrations. 1 Additionally, in most patients on first-line cART, based on protease inhibitors (PIs), therapy failure cannot be ascribed to PI resistance-associated viral mutations. 2 -4 Possible explanations for these cases of therapy failure may have both a virological and a pharmacological character. Novel mutations may lead to viral resistance not detected or recognized by the current methods of genotyping. Additionally, viral replication may be due to suboptimal drug concentrations in cells or compartments, as potentially caused by ATP-binding cassette (ABC) transporters.
ABC transporters represent a large superfamily of ATPdependent drug efflux pumps, of which 11 have been described to be associated with multidrug resistance (MDR). 5 Most prominent members include MDR1 P-glycoprotein (P-gp, ABCB1), MDR protein 1 (MRP1, ABCC1) and breast cancer resistance protein (BCRP, ABCG2) that have proven capacities to efflux various cytostatic and immunosuppressive drugs. 6 ABC transporters are differentially expressed in many different cell types, such as cells in the gut mucosa, cells of the blood -brain and blood-testis barriers, endothelium cells, and lymphocytes and macrophages. 7 ABC transporters may therefore each make a different contribution to the biodistribution and effectiveness of drugs. The presence of these transporters on cancer cell membranes, either since onset or enhanced by cytostatic drug treatment, renders these cells resistant to the used drugs, potentially leading to therapy failure. Recently it was shown that ABC transporters may also play a role in therapy failure of other diseases, e.g. rheumatoid arthritis and epilepsy. 8, 9 A role for ABC transporters has also been suggested in therapy failure in HIV, especially in those cases with normal plasma drug concentrations and proper adherence, in the absence of viral resistance-associated mutations. 10 -12 Efflux of HIV drugs from the viral target cells, i.e. CD4-positive lymphocytes and macrophages, or from certain body compartments, such as the CSF, would lead to subtherapeutic intracellular or intracompartmental drug concentrations, allowing unhampered viral replication. More detailed knowledge of the contribution of the various ABC transporters to the efflux of antiretroviral drugs is thus needed to address incidental HIV therapy failures.
In particular, it is still unclear whether PIs, representing a prominent class of antiretroviral drugs, are substrates of ABC transporters. Earlier studies on the transport of some of the PIs available nowadays by ABC transporters have predominantly focused on MDR1 P-gp, 13 -20 and to a lesser extent on MRP1 21, 22 and BCRP. 23, 24 For MDR1 P-gp, it was reported that PIs can be transported, but only to a limited extent; a 1.1-to 3-fold higher transport 15, 17, 19 was observed when a cell line with MDR1 P-gp overexpression was compared with its parental cell line. For MRP1, transport of PIs was not consistently shown, 25 -27 and for BCRP no transport of PIs was observed. 23 However, in vitro studies have suggested that PIs, although being poor substrates, might still act as blockers of these three ABC transporters. 18,20,22 -24 This would imply that PIs could hamper the physiological function of these and potentially other ABC transporters. Additionally, by blocking ABC transporters, PIs could interact with drugs that are efficient ABC transporter substrates. 28 In this study we selected the three most commonly used PIs, atazanavir, lopinavir and ritonavir, to further investigate whether they are capable of blocking ABC transporters and/or can be substrates for a broad panel of ABC transporters. Whereas atazanavir and lopinavir are actually prescribed as active PIs, ritonavir nowadays is only added in a low dose as a pharmacokinetic enhancer of other PIs because of its ability to block cytochrome P450 3A4, 29 thereby increasing the concentration of most of the PIs. As a readout system for blocking by and transport of the PIs, we used cell growth inhibition assays. First, we tested atazanavir, lopinavir and ritonavir in cell lines with overexpression of MDR1 P-gp, MRP1 and BCRP to verify their ability to block transport of cytotoxic substrates and compare them with well-known blockers of the respective ABC transporters. Secondly, we used a broad panel of cell lines, each overexpressing one of the ABC transporters MDR1 P-gp, MRP1-MRP9 (ABCC1 -6 and ABCC10-12) or BCRP, to explore their actual ability to transport these three PIs.
Materials and methods

Reagents
Atazanavir was extracted from atazanavir 200 mg capsules manufactured by Bristol-Myers Squibb (Princeton, USA). The contents of a capsule were dissolved in 20 mL of dichloromethane. The solution was filtered through filter paper, after which the dichloromethane was evaporated by blowing in a stream of nitrogen. The precipitate was dissolved in 5 mL of ethanol and stored at 2208C. The atazanavir stock solution had a concentration of 2.34 mM measured by HPLC. Lopinavir and ritonavir were donated by Abbott (Chicago, USA). Both compounds were dissolved in ethanol (stock concentration of 14 mM) and stored at 2208C.
All chemicals and drugs used were from Sigma Chemical Co. (St Louis, MO, USA), unless stated otherwise. Mitoxantrone was purchased from AHP Pharma BV (Hoofddorp, The Netherlands), doxorubicin from Farmitalia Carlo Erba (Brussels, Belgium), trichloroacetic acid from ICN Biomedicals Inc. (Aurora, USA) and MK571 from Alexis Biochemicals (Grü nberg, Germany); Ko143 was obtained from Professor G. J. Koomen (University of Amsterdam, The Netherlands).
Cell lines
The human MCF-7 breast cancer cell line and its sublines MCF-7/Dox40 with MDR1 P-gp overexpression, selected with 400 nM doxorubicin, and MCF-7/MR cells with BCRP overexpression, selected with 80 nM mitoxantrone, were obtained from Dr W. S. Dalton (University of South Florida, Tampa, USA). 30 34 were kindly provided by Professor P. Borst (Netherlands Cancer Institute, Amsterdam, The Netherlands). Chinese hamster ovary (CHO) cells and MRP6-transfected CHO/MRP6 cells were kindly provided by Dr G. Kruh (Fox Chase Cancer Center, Philadelphia, USA). 35 As described, for cell growth inhibition experiments, CHO/MRP6 and the parental CHO cells were grown in the presence of 2 mM sodium butyrate for 24 h in order to up-regulate MRP6 expression, and the next day trypsinized cells were washed and resuspended in medium lacking sodium butyrate.
35 MRP7-transfected HEK/MRP7 cells were generated by Dr G. Szaká cs (Hungarian Academy of Sciences, Budapest, Hungary) using an MRP7 expression vector, kindly provided by Dr G. Kruh. 36 MRP8-transfected HEK/MRP8 and MRP9-transfected HEK/MRP9 cells were kindly provided by Professor P. Borst.
37
All cells were maintained at 378C in a 5% CO 2 incubator in either RPMI 1640 or DMEM supplemented with 10% fetal calf serum, 2 mM L-glutamine and 100 mg/L penicillin and streptomycin. All cell lines were routinely checked for the absence of mycoplasma infection. (Over)expression of the ABC transporters was confirmed by immunohistochemistry using specific monoclonal antibodies. 32 
Cell growth inhibition assays-PIs as blockers of ABC transport
Cell suspensions of the ABC transporter-overexpressing cell lines MCF-7/Dox40 (P-gp), 2008/MRP1 (MRP1) and MCF-7/MR (BCRP) and their respective parental cell lines were pre-incubated with or without the PIs atazanavir, lopinavir or ritonavir, all at 5 mM, representing their maximum non-toxic concentration. 24, 38 Additionally, for each of the ABC transporters established blockers were included at their respective maximum non-toxic concentrations, i.e. 10 mM verapamil (MDR1 P-gp), 30 mM MK571 and 500 mM probenecid (both MRP1 blockers) and Protease inhibitors and ABC transporters 1673 JAC plicate in a volume of 200 mL in 96-well plates at a density of 5000 cells per well in the presence of a concentration range of the MDR1 P-gp and MRP1 substrate doxorubicin (0-50 mM) or the BCRP substrate mitoxantrone (0-10 mM). After 96 h, cell survival was determined using the sulphorhodamine B method. 39 The cellular resistance factor (RF) was calculated as the ratio of the IC 50 (concentration of the compound that inhibits cell growth by 50%) of the ABC transporter-overexpressing cells and the IC 50 of the parental cells.
Cell growth inhibition assays-PIs as ABC transporter substrates
ABC transporter-overexpressing sublines and their parental cell lines were plated in triplicate in a volume of 200 mL in 96-well plates at a density of 5000 cells per well in the presence of a concentration range of atazanavir, lopinavir and ritonavir (range 0 -75, 0 -50 and 0-60 mM, respectively). As positive controls for transport function, established substrates were added in parallel experiments, i.e. doxorubicin for P-gp, MRP1 and MRP2, and mitoxantrone for BCRP. After 72-96 h, cell survival was determined using the sulphorhodamine B method 39 for the adherent cells (MCF-7, CHO and 2008) and the XTT method 40 for the semi-adherent HEK293 cells. In the latter, 25 mg of XTT mixed with 0.15 mg of phenazine methosulphate in 25 mL of cell medium was added per well for 3 -4 h. For each ABC transporter, cell growth inhibition experiments were performed 2 -5 times. The RF was calculated as described above. An RF from 1.3 to 1.9 was considered low-level resistance, an RF from 2.0 to 9.9 as moderate-level resistance and an RF≥ 10.0 as high-level resistance. An RF, 0.8 was considered as increased sensitivity.
Results
PIs are efficient blockers of MDR1 P-gp, MRP1 and BCRP
The hypothesized ability of PIs to block substrate transport by major ABC transporters was investigated in cell growth inhibition assays. As shown in Figure 1 , the resistance of cell lines overexpressing MDR1 P-gp (Figure 1a Calculated IC 50 values and RFs for all tested combinations are shown in Table 1 . The RF of MDR1 P-gp-overexpressing MCF-7/Dox40 cells for doxorubicin was decreased from 116 to 3.2 with addition of the MDR1 P-gp blocker verapamil. RFs were also markedly decreased in the presence of the PIs: 23 for atazanavir, 13 for lopinavir and 20 for ritonavir. Using the MRP1-overexpressing 2008/MRP1 cells, the RF for doxorubicin (54) dropped substantially with the established blockers MK571 (19) and probenecid (20) . Interestingly, similar levels of chemosensitization were observed when atazanavir (18) , lopinavir (20) and ritonavir (13) were added. Regarding BCRP, the RF of MCF-7/MR cells for mitoxantrone decreased from 1650 to 75 with Ko143, while distinct but lower reduction of cytotoxicity was observed with atazanavir (792), lopinavir (1125) and ritonavir (1125). These results show that the PIs atazanavir, lopinavir and ritonavir are potent inhibitors of both MDR1 P-gp and MRP1, and to a lesser extent of BCRP.
PIs are poor substrates for a panel of 11 ABC transporters
To determine whether MDR1 P-gp, MRP1 and BCRP as well as other less commonly studied ABC transporters can efflux PIs, 72 -96 h growth inhibition assays were performed with atazanavir, lopinavir and ritonavir in a panel of 11 different ABC transporter-overexpressing cell lines. For the PIs, the used concentration ranges showed sigmoid growth inhibitory curves, as expected, for all sublines tested. The calculated IC 50 values and RFs are presented in Table 2 . In general, four profiles of PI growth effects were found: increased sensitivity (RF: ,0.8); no resistance (RF: 0.8 -1.2); low-level resistance (RF: 1.3-1.9); and moderate-level resistance (RF: 2.0-9.9). Representative growth curves of these observed profiles are shown in Figure 2(a -d) , respectively. Of note, the substrate vehicle ethanol did not influence cell growth in any of the cell lines in a volume equivalent to the highest concentration of PIs used.
The complete overview of observed RFs of the panel of ABC transporter-overexpressing cell lines for atazanavir, lopinavir and ritonavir is shown in Figure 3 . In general, the highest RFs were observed in sublines tested for atazanavir (Figure 3a) . Also for this PI, resistance was observed in the highest number of transporter-overexpressing cell lines; cells with overexpression of MDR1 P-gp, MRP3, MRP4, MRP5, MRP6 and MRP9 showed lowto moderate-level resistance (RF: range 1.3 -2.6). The highest RFs were observed in MRP6-and MRP9-overexpressing cell lines (2.6 and 2.0, respectively). Other sublines (overexpressing MRP1, MRP2, MRP7, MRP8 and BCRP) did not display resistance to atazanavir, while MRP2-overexpressing cells were slightly more sensitive to atazanavir (RF: 0.7).
For lopinavir (Figure 3b ), only cells with overexpression of MRP7 and MRP9 showed low-level resistance (RF: 1.5 and 1.4, respectively). Other ABC transporter-overexpressing cell lines were found not to be resistant to lopinavir. Interestingly, cells with overexpression of MRP6 were more sensitive to lopinavir (RF: 0.6).
Finally, for ritonavir (Figure 3c ), only cells with overexpression of MRP9 showed low-level resistance (RF 1.4). Other ABC transporter-overexpressing cell lines were not resistant to ritonavir. As observed for lopinavir, MRP6-overexpressing cells were more sensitive to ritonavir (RF 0.6).
Taken together, these experiments show that the PIs atazanavir, lopinavir and ritonavir are poor efflux substrates in a broad panel of ABC transporters.
Discussion
In HIV treatment, therapy failure is often caused by viral resistance-associated mutations. In the case of good adherence and appropriate plasma drug concentrations, other mechanisms may be important for the therapy failure. Here, we investigated the possible contribution of ABC transporters, known to play a role in cellular resistance to anticancer drugs. Some investigators had obtained results suggesting that, paradoxically, PIs are blockers of several ABC transporters, but nevertheless cannot be efficiently effluxed by these transporters. 21, 23, 26 Here, we confirmed that three commonly used PIs (atazanavir, lopinavir and ritonavir) are indeed potent blockers of MDR1 P-gp and MRP1, notably to an extent comparable to common ABC transporter Of course, there are limitations to the translation of such in vitro study results to the clinical situation. In particular, the PI concentrations which had clear effects on cell growth are above those that occur in clinical situations unless transiently, while our cells were exposed to these concentrations for 72 -96 h. Furthermore, cell lines were used with supraphysiological expression of ABC transporters. However, our screening models were deliberately chosen to increase the chances of detecting putative interactions between the tested PIs and the ABC transporters.
Usually, compounds that are blockers of an ABC transporter exert their effect by acting as competitive substrates, or compete with ATP-binding sites of this transporter. In this context, our finding that PIs are blockers but are not efficiently effluxed by MDR1 P-gp, MRP1 and BCRP indicates that PIs do not operate as classical blockers of these transporters. Gupta et al. 23 were the first to report this property for PIs in a BCRP-overexpressing cell line. Interestingly, a recent study showed that introduction of lopinavir-based cART in HIV-infected patients was accompanied by a blockage of the intestinal MDR1 P-gp activity, resulting in a 2-fold increase in digoxin exposure as revealed by the area under the curve. 41 The apparent lack of efficient efflux of atazanavir, lopinavir and ritonavir by the MDR1 P-gp-overexpressing subline MCF-7/Dox40 is noteworthy in light of earlier reports suggesting that lopinavir and ritonavir can be transported by MDR1 P-gp using growth inhibition and transwell transport assays, 15, 19 as well as using human peripheral blood mononuclear cells and murine models. 13,17,42 -44 This may relate to even higher sensitivity of the used radioactively labelled PI-based transport assays in some of these studies. Still, the reported level of transport of lopinavir and ritonavir by MDR1 P-gp varied and was, similarly to our findings, quite low (1.1-3-fold compared with parental cells). 14 -17 Undoubtedly, the sensitivity of the growth inhibition assay is dependent on the expression levels and functionality of the transporters in the cell lines used. For all sublines in our studies, including MCF-7/Dox40, ABC transporter expression was confirmed by immunohistochemistry and, for those sublines with an established ABC transporter substrate available, functionality was confirmed by a marked resistance to the control Table 2 . Bierman et al.
substrates. Of note, we detected minor but distinct MDR1 P-gp-mediated transport of atazanavir, as revealed by an increased IC 50 (see Table 2 , RF 1.5). Actually, atazanavir was the PI showing modest efflux by a wide range of ABC transporters, in contrast to lopinavir and ritonavir, which appeared to be poor substrates for most ABC transporters tested. Whether small Table 2 ) from IC 50 Protease inhibitors and ABC transporters differences in chemical structure account for these findings remains to be established. Of note, atazanavir differs from other peptidomimetic PIs by its C-2 symmetric chemical structure. Importantly, the clinical pattern of side effects of atazanavir differs significantly from that of lopinavir, ritonavir and most other PIs. 45 When looking from a virological perspective, atazanavir also has a resistance pattern that differs from the other PIs. 2, 46 As far as data are available for the other ABC transporters tested, our findings are in line with earlier reports showing that PIs are poor substrates for MRP1, MRP3, MRP5 and BCRP, 23,25 -27 but do not confirm a putative role for MRP2 in transporting PIs. 25, 26 MRP6 stands out since this transporter appeared to mediate distinct cellular resistance to atazanavir but rather increased sensitivity to the other PIs. Increased sensitivity to a drug in ABC transporter-overexpressing cell lines seems unexpected, but has been reported before. 47, 48 A study by Bergman et al. 47 showed that increased sensitivity of MDR1 P-gp-and MRP1-overexpressing cell lines to the anticancer drug gemcitabine was due to increased activity of the enzyme that phosphorylates gemcitabine (deoxycytidine kinase), thereby potentiating its cytotoxicity. In a similar way, MRP6 could mediate the extrusion of an intracellular metabolite that protects against toxicity by lopinavir and ritonavir. Thus, the toxicity of these PIs would be enhanced in MRP6-overexpressing cells. The pharmacological role of MRP6 in MDR and HIV treatment warrants further evaluation. Recently, MRP6 was found to transport several anticancer drugs, such as etoposide and doxorubicin. 35 MRP7 can confer cellular resistance to some chemotherapeutic agents, e.g. docetaxel (9-to 13-fold resistance) and to nucleotide analogues. 49, 50 With respect to the latter class of drugs, this might point to interactions between lopinavir and nucleotide reverse transcriptase inhibitors (NRTIs), such as tenofovir, which is one of the preferred drug combinations in cART. Interestingly, the combination of PIs with tenofovir is associated with a greater decline in renal function, through an unknown mechanism. 51 Conceivably, lopinavir may increase the tubular tenofovir concentration and provoke toxicity via competition for MRP7, which is expressed in the kidney. 50 Additionally, similar drug interactions may also proceed via competition for MRP4, since our data indicate that another PI, atazanavir, is a substrate for MRP4. MRP4 is highly expressed in the proximal tubules of the kidney and is responsible for renal clearance of tenofovir. 52 Finally, MRP9 appeared to be the only transporter capable of effluxing all three PIs. Thus far, MRP9 expression has only been demonstrated in murine and boar sperm, and no substrate profile of MRP9 has yet been documented. 37 Whether or not MRP9 could influence the PI concentration in semen is unknown. However, since HIV does not replicate in sperm cells, its presence in semen is potentially due to spill-over from the blood or luminal lining cells 53 and may not determine clinical outcome.
On a final note, interference of PIs with ABC transporters may also affect immune functions. Some endogenous substrates that are transported by ABC proteins have been shown to play important roles in the differentiation, maturation and migration of immune cells. 54 For example, cysteinyl leukotriene C 4 , which facilitates the migration of immune cells to lymph nodes, 55 is transported by MRP1-MRP4 and MRP7-MRP9. In view of the blocking effects of PIs on the ABC transporters MDR1 P-gp, MRP1 and BCRP observed in this study, the possible risk of immunosuppressive side effects of PI treatment should be taken into consideration. Noteworthy in this respect is the reported rise in the prevalence of non-AIDS-defining malignancies in the cART era. 56 In conclusion, our study confirms and extends earlier findings that ABC transporters may only play marginal roles in therapy failure of PI-based HIV treatment via the efflux of PIs. Still, the relevance of PI interactions with ABC transporters is highlighted and certainly warrants further investigations into possible interactions with viral suppression of PIs using HIV-infected cellbased assays. Additionally, further studies could focus on the involvement of ABC transporters in drug-specific side effects and drug-drug interactions, and explore if the transporters are responsible for concomitant immunosuppressive effects.
